Ignite Creation Date:
2024-05-06 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 2:16 PM
Study NCT ID:
NCT05092360
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-28
First Post:
2021-10-13
Brief Title:
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer ARTISTRY-7
Sponsor:
Mural Oncology Inc
Organization:
Mural Oncology Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Platinum-resistant Ovarian Cancer |
| Fallopian Tube Cancer |
| Primary Peritoneal Cancer |
Keywords:
| Name | View |
|---|---|
| gemcitabine | View |
| PROC | View |
| EOC | View |
| ALKS 4230 | View |
| IL-2 | View |
| Ovarian Cancer | View |
| KEYNOTE-C71 | View |
| Platinum Resistant | View |
| Epithelian Ovarian Cancer | View |
| Nemvaleukin alfa | View |
| Pembrolizumab | View |
| ARTISTRY-7 | View |
| ART-7 | View |
| paclitaxel | View |
| pegylated liposoma doxorubicin | View |
| PLD | View |
| topotecan | View |
| gemzar | View |